-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Neutral on Conmed, Raises Price Target to $45

Benzinga·07/30/2026 18:13:22
Listen to the news
Piper Sandler analyst Matt O'Brien reiterates Conmed (NYSE:CNMD) with a Neutral and raises the price target from $39 to $45.